Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
During the last 4 trading days we went thru approx 210 million that is more then the whole float. I suggest to everyone hang on we go up from here. I would tend to believe that those who sold have done so and those who accumulated are doing just that.
So if that is correct then those who average in above 6.00 are looking for 12.00 before selling any.....glty
I wonder if Lorc-phen if you will have to detox also ?
fire at will! lol
yeah
qnexa is so safe that after 90 days its mandatory u detox from the phentermine..lollollollollolool
I am still convinced that the hedgers still need to get as much shares as possible. Articles like what you are reading are gonna hit the airwaves in an attempt to bring down the share price. Like I mentioned earlier I have some dry powder........bring it on !!!
Even if the drug is approved next month, analysts believe the company will be required to perform post-approval studies regarding cardiovascular risks.
analysts?..lol ...you mean bloggers parading around like they know WTF is going on as they did prior to adcom?
There were no cardio problems with 8000 tested and 20,000 electro cardiograms
Meanwhile, Vivus' Qnexa is expected to hit the U.S. market first. That and Qnexa's superior efficacy will make it "the obesity therapy of choice," wrote Leerink Swann analyst Steve Yoo in a research note published Friday.
wow this guy is on top of it isnt he not a Q..VVUS has no manufacturing set up for Qnexa... where by ARNA does.. Lorcaserin is in line for 1st approval dibs most likely... and as stated in the CC, they are ready to roll now superior efficacy..yeah baby!!!!...qnexa BSBSBS weigh the risks
Also working against lorcaserin are questions about whether an echocardiogram – a sonogram of the heart —should be required before the drug is prescribed. It's a costly test, and added to "the lower efficacy compared to Qnexa could limit lorcaserin's use," wrote Oppenheimer analyst Bret Holley in a research note published Friday.
Heres another clown..these ideas came from 3 maybe 4 panel members while the FDA mentioned nothing about any of this in their presentation in the AM of adcom
I thinks its highly questionable how much more they will have to do concerning the heart valve deal..but arena did say they were prepared to do whatever is required, during their am presentation prior to idiots rambling on about nothing...and it would all be post approval
Of course, obesity is a lucrative market for drug makers, and could offer plenty of room for multiple therapies. And even a runner-up drug can generate big sales. And Leerink's Yoo upgraded Arena to Outperform predicting that lorcaserin could hit the market by next March.
a runner up my azz...if the risks are laid out to the patient...lorquess verses qnexa especially to a woman, I would have to bet for that extra 1 to 2 percent weight loss, she'd be reaching for lorcaserin
lets see..should I risk clef pallet to a new born and possibly a heart attack with qnexa, or, should i put up with headache that disappears after a few days and ther e is no detox with lorqess? and march poopy cock..how bout sept it gets into the market
then theres the detox mandatory after 90 days cause of the phentermine... and topiramate is for epilepsy and does nothing for weight loss on its own...another complete joke of an issue blown out of the water...maybe I should become a freakin analyst.lollool
Contrave is out in Pluto territory and has no bearing on this for the next 1 to 2 years..
so the stock will remain volatile.
wow wow wow ...tell me something I dont know!!!!
I think you are very correct.
Hard to go down now with FDA panel vote a yes on this at 18-4. Hedge funds and big boys are more confident once they see a dip they'll buy in. So I'm seeing this at a flat line or steadily climb until June 27 and another major kaboooom after ARNA/Eisai PR some #s and dates to get things rolling...
Sweet, it needed a breather anyhow. And the PPs still looks good. Maybe we start our run soon.......glty
volume/pps reminds me exactly like hgsi back in 2009. it never looked back from $3 to $40...
Not bad after a huge up day to stay even, I consider that positive by the way. IF, Hedge funds can drive it down to get cheaper shares they will. Otherwise they will load up with what ever they can, this IMO, and that is all it is (MY OPINION)when the hedgers begin we move north you will be able to tell. Just be ready.....I think cause everyone was ready prior to ADCOM we caught them off guard......hahahaha
So, I believe ARNA is being closely watched. No hanky panky here....
If we go down to the wire folks try to get some dry powder ready just in case. Whatever the PPS is about a week prior to PDUAF date, then figure about .50-.75 cents lower and put in an order for whatever you have. Sooooooooo if they decide to Raid ARNA, we will catch them again.....MY plan anyway.
glty
After hours buying just started...
http://www.nasdaq.com/symbol/arna/after-hours
No volume after hrs today. : /
It didn't go crazy up or down over the last month until real News, I think it will do the same this time. Maybe not too crazy. Little steps up would work just fine for me. Go ARNA
Is this still trading my TDameritrade is stuck ?
Disregard it came back.....
I sure as heck hope it gets to $5.50 in one final bear raid prior to 6/27! I'm really hoping to get one more lot in my cash account, looking at my options right now on what I could sell (at a loss) there to free up some cash. I know, a total reversal from what I've been preaching here about taking some profits when you have them just to be safe....but the BD's were so freaking good, and the FDA's behavior/words at the Adcom were so positive (ignoring the obvious dummies on the panel), I'm absolutely certain we get approved WITHOUT a REMS or a delay, and the pps rockets upwards. Being able to buy shares right here at $6.60 is a steal in it's own right - instant double on approval, goes to $12 - $15 on the June 28th.
It's like a huge magnet @ 6.60
Lol I hear ya ;) $$
yeah but arna has some other gaps that never filled
so with this one can never tell
i sure would not mind seeing it filled..lol
That gap is a lil worry some - MM love to fill em : /
Yeah I agree - still watching closely and contemplating different exit an entry points and profit taking at this point ..
At any time it old explode or implode its really anyone's guess which way - my crystal ball is in the shop lol
I think its gonna see 5.50 before it sees 7.50 without something to ignite it..
I dont expect early approval, but I also dont expect any delay issues with this...
I believe there will be some decent re entry points between now and june 27th
I dont think the FDA will turn down lorcaserin and plan to play it that way when the time is right.
gl
well maybe they are
i thinks its more like guys writing to hear themselves talk
thats unbelievably embarrassing journalism
the folks with the money that is pouring into ARNA , dont read freakin barons to get there info rest assured
I agree, that's why I stated what I said. It's like Barrons is pro VVUS.
Dont forget even up to the DAY of ADCOM meeting, people and hedge funds were all favoring our competitors. Just be satisfied with your DD. Cause it could get rocky we still have over 5 weeks before the actual day. What I am hoping for is the FDA to approve Lorcaserine early.....that would catch everyone off guard and this would POP so big you could hear it around the world......LOL
that article is so freakin inaccurate its worse than pathetic...
the FDA in my mind didnt show up to adcom with any heart worry issues..
it was only in the minds of the panel members that DIDNT know sheet about what they were there for
there were no heart issues period after 20,000 electro cardiograms.
the big deal was the rat cancer issue that was finally buried..
qnexa is safer than lorqess my azz
kaul imo LOOKED LIKE A FOOL AT ADCOM
Why do I feel the Barrons article is favoring the competitors?
<Investors are still giddy about last week's vote by an FDA advisory panel to support Arena Pharmaceuticals' experimental obesity drug.
The advisory committee's 18-4 vote (with one abstention) late Thursday recommending the agency approve the drug is a big win for Arena Pharmaceuticals (ticker: ARNA). The company is among a group of drug makers with new weight-loss drugs that the FDA could allow on the market after years in which no new treatments were approved.
After more than doubling last week – with shares surging 73% on Friday alone -- the stock rose another 4% to $6.61 in Monday afternoon trading.
The market is essentially saying that FDA approval is a done deal. And the agency traditionally does follow the advice of its advisory panel, though it's not required.
Still, investors should think twice before chasing this stock at current levels given that Arena and its drug lorcaserin still face several hurdles including the need to address lingering safety concerns and competition from a rival drug considered safer and more efficacious.
As is often the case with highly anticipated new drugs, euphoria drives expectations. The potential market for an effective and safe weight-loss drug is indeed enormous given that more than a third of adult Americans are obese and another third is overweight.
But the key words to remember are "safe" and "effective." The field is littered with the corpses of failed efforts by other drug companies.
Lorcaserin is one of three drugs vying for FDA approval. Vivus (VVUS) and Orexigen Therapeutics (OREX) are also seeking approval for their obesity medications. And it could be quite a battle.
In February, an advisory committee recommended the agency approve Vivus' drug Qnexa for weight loss. The FDA hasn't acted on it yet.
The federal agency rejected Arena's lorcaserin in 2010, citing "modest weight loss" and concerns about a study that linked the drug to mammary tumors in rats. Arena returned to the FDA with new data showing that 38% of patients on the drug had weight loss of 5% or more in a year, compared with 16% of patients on a placebo.
The FDA is slated to render a decision on June 27, though that could get delayed.
Even if the drug is approved next month, analysts believe the company will be required to perform post-approval studies regarding cardiovascular risks.
Meanwhile, Vivus' Qnexa is expected to hit the U.S. market first. That and Qnexa's superior efficacy will make it "the obesity therapy of choice," wrote Leerink Swann analyst Steve Yoo in a research note published Friday.
Also working against lorcaserin are questions about whether an echocardiogram – a sonogram of the heart —should be required before the drug is prescribed. It's a costly test, and added to "the lower efficacy compared to Qnexa could limit lorcaserin's use," wrote Oppenheimer analyst Bret Holley in a research note published Friday.
Of course, obesity is a lucrative market for drug makers, and could offer plenty of room for multiple therapies. And even a runner-up drug can generate big sales. And Leerink's Yoo upgraded Arena to Outperform predicting that lorcaserin could hit the market by next March.
But given the big move by Arena's stock price last week, caution is warranted. Investors don't react well to doubt or disappointment, so the stock will remain volatile.
And with so many once high-flying drug stocks eventually falling victim to gravity, a little caution in this case could go a long way.>
http://online.barrons.com/article/SB50001424053111904571704577404260758760068.html?mod=BOL_hpp_highlight_top
You it that right - hoping for m prediction though !!!
as the churn turns
one things for sure
at this vol
its going to do one of the other
turn up or turn down
its a dice roll
I'm thinking we see a push from 6.60 upwards- .75 strong resistance if I'm reading he chart correctly lmao @ myself
the stock looks as if its "churning"...
Yes, they do. I had almost set one at $6.50 Thank goodness, I have another chance. We need to get over $6.77 Surprisingly tight range in my opinion given Friday and other factors.
They love tripping stop losses- don't they :) $$$
Amazing- I had scratched out the exact same calculation before reading your post, OldManWins!
I've been scratching numbers for 35 years as a physical commodities trader.
Marked ya!
MG
Very nice trading today !!!
ARNA
Opening Trades 6.46 ave are good now. ::)))watch and wait for the next Trade (TLD)
::)))
Chart looks strong IMO - GLTY
Crazy morning - WOW ARNA
orexigen competition that is
ARNA will be the first to market and last i looked theirs plenty of customers for the product....ARNA has another 50-60% upside......strong buy.......rareF
orexigen is no compensation at this point whatsoever period.
and vvus at the stage theyre at, is at a disadvantage in several ways
no manufacturing set up....the risks with the drug are numerous combined with detox requirements after 90 days
I could go on
VVU# had a breakaway gap and so will ARNA imo
I am very new to active trading and this board but thankfully have made a good profit on ARNA thanks mostly to the board. In pre-trading why are the lots so small. I would have thought institutional and high net worth investors would be trading large blocks.
31 Estimated Trading days left, If FDA doesn't approve earlier.
Followers
|
259
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
22684
|
Created
|
03/27/07
|
Type
|
Free
|
Moderators |
ARENA PHARMACEUTICALS, Inc. (ARNA)
http://www.arenapharm.com/
http://finance.yahoo.com/q/h?s=ARNA
http://www.secform4.com/insider-trading/1080709.htm
Arena Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of oral drugs for cardiovascular, central nervous system, inflammatory, and metabolic diseases. It is developing a pipeline of compounds targeting orphan G protein-coupled receptors using its drug discovery technologies, including constitutively activated receptor technology and Melanophore technology. The company?s drug candidate, lorcaserin hydrochloride, is in Phase 3 clinical trial program for the treatment of obesity. Its other lead development programs include APD125, a 5-HT2a serotonin receptor inverse agonist, which is in Phase 2 clinical trail for the treatment of insomnia; APD791, an anti-thrombotic drug candidate, which is in preclinical development stage for the treatment of arterial thromboembolic diseases, such as acute coronary syndrome. The company has collaboration agreements with Ortho-McNeil Pharmaceutical, Inc. for developing APD668, an orally administered drug candidate, which is under clinical development for the treatment of type 2 diabetes and other disorders; and with Merck & Co., Inc. for the development of MK-0354 for atherosclerosis and related disorders. Arena Pharmaceuticals was incorporated in 1997 and is based in San Diego, California.
http://finviz.com/quote.ashx?t=arna
>
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |